CATALOGO DEI PRODOTTI DELLA RICERCA

BERTOLDO, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.738
EU - Europa 7.634
AS - Asia 5.730
SA - Sud America 898
Continente sconosciuto - Info sul continente non disponibili 181
AF - Africa 162
OC - Oceania 16
Totale 24.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.453
RU - Federazione Russa 2.361
SG - Singapore 2.283
GB - Regno Unito 2.010
CN - Cina 1.651
IT - Italia 949
BR - Brasile 717
VN - Vietnam 504
HK - Hong Kong 460
SE - Svezia 443
DE - Germania 416
FR - Francia 415
FI - Finlandia 350
IE - Irlanda 325
KR - Corea 179
BD - Bangladesh 124
CA - Canada 116
UA - Ucraina 113
IN - India 95
TR - Turchia 84
ID - Indonesia 69
AR - Argentina 60
NL - Olanda 53
JP - Giappone 47
NG - Nigeria 43
MX - Messico 42
AE - Emirati Arabi Uniti 37
ZA - Sudafrica 34
EC - Ecuador 29
IQ - Iraq 27
CR - Costa Rica 26
ES - Italia 26
PK - Pakistan 21
PL - Polonia 21
BE - Belgio 20
CL - Cile 20
CO - Colombia 20
VE - Venezuela 20
RO - Romania 18
PH - Filippine 17
AT - Austria 16
EE - Estonia 16
EG - Egitto 16
IL - Israele 15
LT - Lituania 15
MY - Malesia 15
GT - Guatemala 14
PR - Porto Rico 14
SV - El Salvador 14
TT - Trinidad e Tobago 14
AU - Australia 13
HN - Honduras 13
CZ - Repubblica Ceca 12
IR - Iran 12
PY - Paraguay 12
CW - ???statistics.table.value.countryCode.CW??? 11
JM - Giamaica 11
MA - Marocco 10
NI - Nicaragua 10
UZ - Uzbekistan 10
BJ - Benin 9
JO - Giordania 9
KE - Kenya 9
SA - Arabia Saudita 9
SC - Seychelles 9
DZ - Algeria 8
OM - Oman 8
HR - Croazia 7
PE - Perù 7
SK - Slovacchia (Repubblica Slovacca) 7
UY - Uruguay 7
AM - Armenia 5
BG - Bulgaria 5
BH - Bahrain 5
BO - Bolivia 5
KZ - Kazakistan 5
TG - Togo 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CH - Svizzera 4
GA - Gabon 4
HU - Ungheria 4
LB - Libano 4
LV - Lettonia 4
PT - Portogallo 4
RS - Serbia 4
TH - Thailandia 4
DK - Danimarca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GP - Guadalupe 3
IS - Islanda 3
MM - Myanmar 3
NP - Nepal 3
SI - Slovenia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
AL - Albania 2
AZ - Azerbaigian 2
Totale 24.158
Salva come PNG Salva come JPEG
Città #
Southend 1.775
Ashburn 1.257
Singapore 1.205
Jacksonville 982
San Jose 866
Chandler 815
Moscow 698
Dallas 633
Hong Kong 448
Ann Arbor 388
Woodbridge 377
Houston 329
Dublin 320
Council Bluffs 289
Verona 279
Beijing 221
The Dalles 191
New York 170
Ho Chi Minh City 167
Princeton 148
Lawrence 147
Los Angeles 146
Wilmington 137
Nanjing 124
Hanoi 110
Jinan 109
Santa Clara 103
Milan 100
Shenyang 97
Buffalo 91
São Paulo 83
Helsinki 76
Hebei 74
Changsha 69
Sindelfingen 69
Boardman 68
Tianjin 67
Munich 54
Nanchang 53
Orem 50
Redondo Beach 50
Bologna 48
Ningbo 48
Tokyo 42
Rome 41
Zhengzhou 41
Abuja 40
London 40
Chicago 39
San Francisco 36
Taizhou 36
Haikou 35
Jakarta 35
Hangzhou 33
Jiaxing 33
Las Vegas 31
Atlanta 30
Brooklyn 30
Columbus 29
Da Nang 28
Montreal 28
Dearborn 27
Phoenix 27
Guangzhou 26
Toronto 26
Denver 25
Frankfurt am Main 24
Lancaster 24
Providence 24
North Bergen 22
Rio de Janeiro 22
San José 21
Falls Church 20
Johannesburg 19
Norwalk 19
Seoul 19
Turku 19
Washington 19
Detroit 18
Haiphong 18
Amsterdam 17
Brussels 17
Florence 17
Fuzhou 17
Mexico City 17
Paris 17
Stockholm 17
Chennai 16
Dong Ket 16
Naples 16
Seattle 16
Taiyuan 16
Belo Horizonte 15
Boston 15
Curitiba 15
Lappeenranta 15
Warsaw 15
Biên Hòa 14
Mumbai 14
Annandale 13
Totale 14.892
Salva come PNG Salva come JPEG
Nome #
Adipocytes IGFBP-2 expression in prepubertal obese children. 345
Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro. 295
Trattamento dell'osteoporosi cortisonica con Nandrolone Decanoato 283
The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation 281
Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells 273
25-hydroxyvitamin D levels in healthy premenopausal wome: association with bone turnover markers and bone mineral density 260
The effects of menopause and estrogen replacement therapy on the renal handling of calcium 257
Age-related bone loss in postmenopausal women 257
The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells 252
Type VI Osteogenesis imperfecta: effect of plasma transfusion on bone metabolism 248
STEAP mRNA detection in serum of patients with solid tumours. 246
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 244
BISPHOSPHONATES DECREASE HTERT IN PC3 AND DU-145 PROSTATE CANCER CELLS 243
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. 243
Bone metabolism in patients with anorexia nervosa and amenorrhoea 242
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 227
A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: Prednisone versus Deflazacort. 222
Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. 219
Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020 213
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 206
Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study 205
Incidenza di ipovitaminosi D nel Nord Italia 203
Histomorphometric analysis of glucocorticoid-induced osteoporosis 203
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone 203
Altered bone metabolism in children infected with human immunodeficiency virus. 201
Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study 199
Bone microarchitecture evaluated by histomorphometry 197
Bone development during GH and GnRH analog treatment 196
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene? 192
Guidelines for the diagnosis, prevention and management of osteoporosis 191
[Use of nonsteroidal anti-inflammatory drugs in patients with vertebral osteoporotic fractures]. 190
Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ) 188
Blood ionized calcium is associated with clustered polymorphism in the carboxyl-terminal tail of the calcium-sensing receptor. 185
Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic 181
Osteopenia induced by immunosuppressive drugs in rats. Histomorphometric analisys of risedronate effects. 179
Prevalence of asymptomatic vertebral fractures in late-onset Pompe disease. 179
Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment 178
Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. 177
In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls 176
Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment 175
ARTROPATIE DISMETABOLICHE 175
Acute effects of deflazacort and prednisone on rates of mineralization and bone formation 173
Hypophosphatasia in adults: A new manifestation, a new mutation. A case report 173
emerging drugs for the management of cancer treatment induced bone loss 172
Bisfosfonati e metastasi ossee:up-to-date 2005 170
Bone Microarchitecture in Mild Primary Hyperparathyroidism 169
The renal handling of calcium: influence of parathyroid hormone secretion 168
[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project] 168
Effects of a 4400 km ultra-cycling non-competitive race and related training on body composition and circulating progenitors differentiation 166
PEAK BONE MASS AND BODY COMPOSITION IN PRECOCIOUS PUBERTY AFTER GNRH AGONIST THERAPY WITH AND WITHOUT CALCIUM SUPPLEMENTATION 165
Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) 165
Impact of the Visceral Adipose Tissue on Bone Quality in Patients with Untreated mild-to-severe Obstructive Sleep Apnoea 164
Valutazione della microarchitettura ossea nell'iperparatiroidismo primitivo 164
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study 164
GAPDH: CONSTITUTIVE HOUSEKEEPING GENE OR TARGET FOR THERAPEUTIC INTERVENTION? 163
EFFETTO DI UN AGONISTA DEL GNRH AD AZIONE PROLUNGATA (LEUPROLIDE ACETATO) SULLO STATO DI MINERALIZZAZIONE OSSEA IN BAMBINE CON PUBERTA' PRECOCE 162
Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. 162
Artropatie dismetaboliche 161
Bone Mineral Density in Mountain, Road Cyclists and Untrained Controls: Exercise, Diet and Hormones 159
Physiopatology of bone metastases 159
Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in Italy 158
Incidenza di ipovitaminosi D nel Nord Italia 158
Biology and Pathophysiology of Bone Metastasis in Prostate Cancer 158
Drug-induced osteonecrosis of the jaw: the state of the art 157
Bone mineral density and metabolism in HIV-infected children 156
Final peak bone mass in precocious puberty after GhRH agonist therapy with and without calcium supplementation 154
YEARS BOOK 2006 . BISFOSFONATI E ONCOLOGIA 153
Sodium requirements regulates renal tubular reabsorption of calcium 152
CALCIUM SUPPLEMENTATION, OESTROGENS AND BONE DENSITY IN GNRHA TREATED PRECOCIOUS PUBERTY 152
Osteomalacia: The missing link in the pathogenesis of Bisphosphonate-related osteonecrosis of the jaws? 152
Vitamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosa 152
The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate 151
The Effect of Bisphosphonates on Gene Expression: The GAPDH as a Housekeeping or a New Target Gene? 150
Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. 149
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma 148
Effects of two oral doses of alendronate in the treatment of Paget's disease of bone 147
Ruolo dei bisfosfonati nella terapia dell'osteoporosi 147
Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. 147
Effetto dell'alendronato sulle caratteristiche strutturali e biomeccaniche dell'osso corticale 146
Relationship between serum calcium, sodium excretion and calcium excretion in normals and in patients with idiophatic hypercalciuria and primary hyperparathyroidism 145
The use of dichloromethylene bisphosphonate and aminobutanebisphosphonate in hypercalcemia of malignancy. 145
the use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemnia of malignanacy 144
The prevention of corticosteroid-induced osteoporosis with nandrolone decantate Bone and Mineral 15, 72-81 (1991) 144
Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools. 141
Transdermal Estradiol in the treatment of postmenopausale bone loss. 140
Transdermal estradiol in the treatment of postmenopausal bone loss. 138
Regulation of calcium-parathyroid hormone feedback in primary htperparathyroidism effcts of bisphosphonate treatment 138
A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis 138
The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study 137
Valutazione della perdita frazionaria di massa ossea dopo la menopausa. 136
Effects of two oral doses of alendronate in the treatment of Paget’s disease of bone. 134
intramuscolar neridronate in postmenopausal women with low bone mineral density 134
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists 133
Relationship between serum calcium, sodium excretion and calcium excretion in normals and in patients with idiopathic hypercalcemia and with primary hyperparathyroidism 132
Fisiopatologia del dolore da metastasi ossea 132
Calcium Supplementation Increases Bone Mass in GH-Deficient Prepubertal Children during GH Replacement 131
Serum 25-hydroxy vitamin D and exercise capacity in COPD. 131
nUOVE PROSPETTIVE NELL'UTILIZZO DEI BISFOSFONATI IN ONCOLOGIA:OLTRE LA METASTASI OSSEA 131
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary 130
The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate 129
Totale 17.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.982
article - articoli 73.419
book - libri 1.355
conference - conferenze 4.120
curatela - curatele 0
other - altro 301
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.787
Totale 165.964
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022656 0 0 0 0 48 48 14 61 37 27 122 299
2022/20232.300 217 196 273 362 227 522 12 134 238 24 73 22
2023/20241.187 53 88 130 135 169 169 58 74 7 50 159 95
2024/20253.140 187 198 113 477 168 75 182 183 460 226 213 658
2025/20268.588 637 465 759 1.352 2.029 550 808 490 755 400 172 171
2026/20272.226 213 339 432 1.231 11 0 0 0 0 0 0 0
Totale 24.359